Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer
By: Jinsong He, Xianming Wang, Hong Guan, Weicai Chen, Ming Wang, Huisheng Wu, Zun Wang, Ruming Zhou and Shuibo Qiu
Open Access
|Apr 2011References
- Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.2007;: 1721-8.
- Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options.2007;: 235-44.
- Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer.2010,: 1938-48.
- Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer - prognostic factors and survival.2011;: 46-52.
- Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer.2007;: 25-32.
- Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW, et al. Triple-negative breast cancers: unique clinical presentations and outcomes.2010;(Suppl 3): 384-90.
- Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, et al. Poly(ADP-Ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer.2010;: 4702-10.
- Wang XM, He JS, Tong JM. Clinical application of preoperative superselective intra-arterial chemotherapy in the treatment of late breast cancer cases.2006;: 136-8.
- Zuo WS.. 2nd edition. Shandong: Shandong Science & Technology Press; 2006. p. 974-9.
- Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.2010;: 133-40.
- Yi SY, Ahn JS, Uhm JE, Lim do H, Ji SH, Jun HJ, et al. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.2010;: 527.
- Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.2006;: 617-21.
- Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer sub-types.2007;: 2329-34.
- Maegawa RO, Tang SC. Triple-negative breast cancer: unique biology and its management.2010;: 878-83.
- Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma.2009;: 1-8.
- Maurer CA, Borner M, Buchler MW. Regional chemotherapy of gastrointestinal cancer.1997;: 9-22.
- Miura T, Takeuchi I, Kikuoka S, Miura T. Intra-arterial infusion chemotherapy for advanced breast cancer - 5 cases of marked response.2009;: 2108-10.
- Vanel D. Interventional radiology: the new daily work of the breast radiologist.2002;: 1.
- Pacetti P, Mambrini A, Paolucci R, Sanguinetti F, Palmieri B, Della Seta R, et al. Intra-arterial chemotherapy: a safe treatment for elderly patients with locally advanced breast cancer.2006;: 761-4.
- Takizawa K, Shimamoto H, Ogawa Y, Yoshimatsu M, Yagihashi K, Nakajima Y, et al. Development of a new subclavian arterial infusion chemotherapy method for locally or recurrent advanced breast cancer using an implanted catheter-port system after redistribution of arterial tumor supply.2009;: 1059-66.
Language: English
Page range: 123 - 128
Published on: Apr 23, 2011
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2011 Jinsong He, Xianming Wang, Hong Guan, Weicai Chen, Ming Wang, Huisheng Wu, Zun Wang, Ruming Zhou, Shuibo Qiu, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.